Novel pyridoindole derivative compound and use thereof
The pyridoindole derivative compound addresses the underlying interaction between Tau and synaptogyrin-3 to prevent or treat tauopathy, providing a fundamental solution by inhibiting the binding of Tau to synaptic vesicles and restoring neurotransmitter secretion.
Patent Information
- Application Number
- PCT/KR2025/014306
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-09-13
- Filing Date
- 2025-09-15
- Publication Date
- 2026-03-19
AI Technical Summary
Current treatments for tauopathy, a neurodegenerative disease caused by hyperphosphorylation and aggregation of Tau protein, primarily focus on symptomatic relief rather than addressing the underlying interaction between Tau protein and synaptogyrin-3, which contributes to the disease's progression.
A novel pyridoindole derivative compound that inhibits the interaction between Tau protein and synaptogyrin-3, blocking the binding of Tau to synaptic vesicles and restoring neurotransmitter secretion.
The compound effectively prevents or treats tauopathy by fundamentally eliminating the etiology of the disease, inhibiting the interaction between Tau and synaptogyrin-3, thereby restoring vesicle mobility and neurotransmitter secretion, offering a therapeutic strategy beyond symptomatic treatment.